Sfoglia per AUTORE
LORUSSO D
Collezione AO Ordine Mauriziano

  

Items : 18

Single-Agent Trabectedin Versus Physician's Choice Chemotherapy in Patients With Recurrent Ovarian Cancer With BRCA-Mutated and/or BRCAness Phenotype: A Randomized Phase III Trial. in Journal of clinical oncology : official journal of the American Society of Clinical Oncology / J Clin Oncol. 2024 May 1;42(13):1488-1498. doi: 10.1200/JCO.23.01225. Epub 2024 Feb 5.
2024
AO Ordine Mauriziano

Lorusso D; Raspagliesi F; Ronzulli D; Valabrega G; Colombo N; Pisano C; Cassani C; Tognon G; Tamberi S; Mangili G; Mammoliti S; De Giorgi U; Greco F; Mosconi AM; Breda E; Artioli G; Andreetta C; Casanova C; Ceccherini R; Frassoldati A; Salutari V; Giolitto S; Scambia G;

MITO END-3: efficacy of avelumab immunotherapy according to molecular profiling in first-line endometrial cancer therapy. in Annals of oncology : official journal of the European Society for Medical Oncology / Ann Oncol. 2024 Jul;35(7):667-676. doi: 10.1016/j.annonc.2024.04.007. Epub 2024 May 3.
2024
AO Ordine Mauriziano

Pignata S; Califano D; Lorusso D; Arenare L; Bartoletti M; De Giorgi U; Andreetta C; Pisano C; Scambia G; Lombardi D; Farolfi A; Cinieri S; Passarelli A; Salutari V; De Angelis C; Mignogna C; Priolo D; Capoluongo ED; Tamberi S; Scaglione GL; Arcangeli V; De Cecio R; Scognamiglio G; Greco F; Spina A; Turinetto M; Russo D; Carbone V; Casartelli C; et alii...

Prescribing pattern of anticoagulants in patients with cancer associated thrombosis: Results of a survey among MITO group and AIOM society. in Tumori / Tumori. 2023 Oct;109(5):490-495. doi: 10.1177/03008916221146820. Epub 2023 Jan 6.
2023
ASL Torino 5
AO Ordine Mauriziano

Artioli G; Valabrega G; Purro A; Mammoliti S; Testa S; Scotto G; Turinetto M; Bellero M; Milani A; Tuninetti V; Pignata S; Biglia N; Scandurra G; Mangili G; Di Maio M; De Giorgi U; Savarese A; Castaldo D; Lorusso D;

Effect of bevacizumab in advanced low grade serous ovarian cancer: Data from the MITO 22 trial. in Gynecologic oncology / Gynecol Oncol. 2023 May;172:72-77. doi: 10.1016/j.ygyno.2023.03.011. Epub 2023 Mar 23.
2023
AO Ordine Mauriziano

Musacchio L; Turinetto M; Arenare L; Bartoletti M; Califano D; Tuninetti V; Marchetti C; Cormio G; Loizzi V; Pisano C; Salutari V; Valabrega G; Priolo D; Cecere SC; Ventriglia J; Raspagliesi F; Perrone F; Fagotti A; Lorusso D; Scambia G; Pignata S;

Randomized phase II BGOG/ENGOT-cx1 study of paclitaxel-carboplatin with or without nintedanib in first-line recurrent or advanced cervical cancer. in Gynecologic oncology / Gynecol Oncol. 2023 Jul;174:80-88. doi: 10.1016/j.ygyno.2023.04.028. Epub 2023 May 9.
2023
AO Ordine Mauriziano

Vergote I; Van Nieuwenhuysen E; Casado A; Laenen A; Lorusso D; Braicu EI; Guerra-Alia E; Zola P; Wimberger P; Debruyne PR; Falcó E; Ferrero A; Muallem MZ; Kerger J; García-Martinez E; Pignata S; Sehouli J; Van Gorp T; Gennigens C; Rubio MJ;

2023
AO Ordine Mauriziano

Colombo N; Gadducci A; Landoni F; Lorusso D; Sabbatini R; Artioli G; Berardi R; Ceccherini R; Cecere SC; Cormio G; De Angelis C; Legge F; Lissoni A; Mammoliti S; Mangili G; Naglieri E; Petrella MC; Ricciardi GRR; Ronzino G; Salutari V; Sambataro D; Savarese A; Scandurra G; Tasca G; Tomao F; Valabrega G; Zavallone L; Pignata S;

Corrigendum: Management of metastatic endometrial cancer: physicians' choices beyond the first line after approval of checkpoint inhibitors. in Frontiers in oncology / Front Oncol. 2024 Jan 22;13:1357793. doi: 10.3389/fonc.2023.1357793. eCollection 2023.
2023
AO Ordine Mauriziano

Arezzo F; Giannone G; Castaldo D; Scotto G; Tuninetti V; Turinetto M; Bartoletti M; Mammoliti S; Artioli G; Mangili G; Salutari V; Lorusso D; Cormio G; Loizzi V; Zamagni C; Savarese A; Di Maio M; Ronzino G; Pisano C; Pignata S; Valabrega G; Arezzo F; Giannone G; Castaldo D; Scotto G; Tuninetti V; Turinetto M; Bartoletti M; Mammoliti S; et alii...

Corrigendum: Optimizing the use of lenvatinib in combination with pembrolizumab in patients with advanced endometrial carcinoma. in Frontiers in oncology / Front Oncol. 2023 Aug 7;13:1232476. doi: 10.3389/fonc.2023.1232476. eCollection 2023.
2023
AO Ordine Mauriziano

Lorusso D; Danesi R; Locati LD; Masi G; De Giorgi U; Gadducci A; Pignata S; Sabbatini R; Savarese A; Valabrega G; Zamagni C; Colombo N;

Management of metastatic endometrial cancer: physicians' choices beyond the first line after approval of checkpoint inhibitors. in Frontiers in oncology / Front Oncol. 2023 Sep 14;13:1247291. doi: 10.3389/fonc.2023.1247291. eCollection 2023.
2023
AO Ordine Mauriziano

Arezzo F; Giannone G; Castaldo D; Scotto G; Tuninetti V; Turinetto M; Bartoletti M; Mammoliti S; Artioli G; Mangili G; Salutari V; Lorusso D; Cormio G; Loizzi V; Zamagni C; Savarese A; Di Maio M; Ronzino G; Pisano C; Pignata S; Valabrega G;

Efficacy and safety of PARP inhibitors in elderly patients with advanced ovarian cancer: a systematic review and meta-analysis. in International journal of gynecological cancer : official journal of the International Gynecological Cancer Society / Int J Gynecol Cancer. 2022 Nov 7;32(11):1410-1418. doi: 10.1136/ijgc-2022-003614.
2022
AO Ordine Mauriziano

Maiorano BA; Maiorano MFP; Lorusso D; Di Maio M; Maiello E;

MEK inhibitor as single agent in low grade serous ovarian and peritoneal cancer: a systematic review and meta-analysis. in Cancer treatment reviews / Cancer Treat Rev. 2022 Nov;110:102458. doi: 10.1016/j.ctrv.2022.102458. Epub 2022 Aug 24.
2022
AO Ordine Mauriziano

Musacchio L; Valsecchi AA; Salutari V; Valabrega G; Camarda F; Tuninetti V; Giannone G; Bartoletti M; Marchetti C; Pignata S; Fagotti A; Scambia G; Di Maio M; Lorusso D;

Clinical characteristics and molecular aspects of low-grade serous ovarian and peritoneal cancer: a multicenter, observational, retrospective analysis of MITO Group (MITO 22). in British journal of cancer / Br J Cancer. 2022 Nov;127(8):1479-1486. doi: 10.1038/s41416-022-01897-1. Epub 2022 Jul 22.
2022
AO Ordine Mauriziano

Musacchio L; Califano D; Bartoletti M; Arenare L; Lorusso D; Losito NS; Cormio G; Greggi S; Raspagliesi F; Valabrega G; Salutari V; Pisano C; Spina A; Russo D; Del Sesto M; Canzonieri V; Ferraù F; Zannoni GF; Loizzi V; Ghizzoni V; Casanova C; Tuninetti V; Ducceschi M; Del Vecchio V; Scalone S; Priolo D; Perrone F; Scambia G; Pignata S; et alii...

Optimizing the use of lenvatinib in combination with pembrolizumab in patients with advanced endometrial carcinoma. in Frontiers in oncology / Front Oncol. 2022 Sep 21;12:979519. doi: 10.3389/fonc.2022.979519. eCollection 2022.
2022
AO Ordine Mauriziano

Lorusso D; Danesi R; Locati LD; Masi G; De Giorgi U; Gadducci A; Pignata S; Sabbatini R; Savarese A; Valabrega G; Zamagni C; Colombo N;

Management of Metastatic Endometrial Cancer: Physicians' Choices Beyond the First Line. A MITO Survey. in Frontiers in oncology / Front Oncol. 2022 May 27;12:880008. doi: 10.3389/fonc.2022.880008. eCollection 2022.
2022
AO Ordine Mauriziano

Giannone G; Castaldo D; Tuninetti V; Scotto G; Turinetto M; Valsecchi AA; Bartoletti M; Mammoliti S; Artioli G; Mangili G; Salutari V; Lorusso D; Cormio G; Zamagni C; Savarese A; Di Maio M; Ronzino G; Pisano C; Pignata S; Valabrega G;

Thromboembolic events and antithrombotic prophylaxis in advanced ovarian cancer patients treated with bevacizumab: secondary analysis of the phase IV MITO-16A/MaNGO-OV2A trial. in International journal of gynecological cancer : official journal of the International Gynecological Cancer Society / Int J Gynecol Cancer. 2021 Oct;31(10):1348-1355. doi: 10.1136/ijgc-2021-002786. Epub 2021 Aug 30.
2021
AO Ordine Mauriziano

Gallo C; Schettino C; Gargiulo P; Greggi S; Distefano M; Bogani G; Nardin M; Lapresa M; Cecere SC; Salutari V; Lorusso D; Katsaros D; Lissoni AA; Scollo P; De Giorgi U; Cinieri S; De Censi A; Breda E; Ferrero A; Lauria R; Gadducci A; Tognon G; Artioli G; Frezzini S; Colombo N; Pisano C; Scambia G; Raspagliesi F; Arenare L; et alii...

Patients' perception of chemotherapy side effects: Expectations, doctor-patient communication and impact on quality of life - An Italian survey. in European journal of cancer care / Eur J Cancer Care (Engl). 2017 Mar;26(2). doi: 10.1111/ecc.12618. Epub 2016 Dec 22.
2017
AO Ordine Mauriziano

Lorusso D; Bria E; Costantini A; Di Maio M; Rosti G; Mancuso A; Lorusso D; Bria E; Costantini A; Di Maio M; Rosti G; Mancuso A;

Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in very platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial. in European journal of cancer (Oxford, England : 1990) / Eur J Cancer. 2015 Feb;51(3):352-8. doi: 10.1016/j.ejca.2014.11.017. Epub 2014 Dec 17.
2015
AO Ordine Mauriziano

Mahner S; Meier W; du Bois A; Brown C; Lorusso D; Dell'Anna T; Cretin J; Havsteen H; Bessette P; Zeimet AG; Vergote I; Vasey P; Pujade-Lauraine E; Gladieff L; Ferrero A;

Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in partially platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial. in Annals of oncology : official journal of the European Society for Medical Oncology / Ann Oncol. 2012 May;23(5):1185-1189. doi: 10.1093/annonc/mdr441. Epub 2011 Oct 5.
2012
AO Ordine Mauriziano

Gladieff L; Ferrero A; De Rauglaudre G; Brown C; Vasey P; Reinthaller A; Pujade-Lauraine E; Reed N; Lorusso D; Siena S; Helland H; Elit L; Mahner S;

©2024 Tutti i diritti riservati. Biblioteca Virtuale per la Salute - Piemonte